U.S. Personal Products Stock News

The market has climbed 2.5% in the last 7 days and 26% over the past year, with earnings forecast to grow by 17% annually. In such a thriving environment, identifying stocks that might be trading below their estimated value can offer opportunities for investors looking to capitalize on potential growth.

Acadia Healthcare Company (NasdaqGS:ACHC) has brought back Debbie Osteen as CEO as part of a turnaround effort. The company is rolling out AI driven billing technology to sharpen revenue cycle processes and address operational friction. These moves come as Acadia responds to regulatory changes and reimbursement pressures that have affected performance. The stock trades at $23.49, with the share price up 64.4% year to date, but down 14.2% over the past month and down 5.7% over the past week...

Over the last 7 days, the United States market has risen 2.5%, contributing to a remarkable 26% climb over the past year, with earnings anticipated to grow by 17% per annum in the coming years. In this thriving environment, growth companies with high insider ownership are particularly noteworthy as they often demonstrate strong alignment between management and shareholder interests, potentially positioning them well for sustained success.

Over the last 7 days, the United States market has risen by 2.5%, and over the past year, it has climbed an impressive 26%. While the term 'penny stock' might seem outdated, these investments still offer intriguing opportunities for those seeking growth in smaller or newer companies with solid financial foundations. In this article, we will explore three penny stocks that stand out due to their strong balance sheets and potential for significant returns.

Over the last 7 days, the United States market has risen 2.5%, contributing to a remarkable 26% increase over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that possess strong fundamentals and growth potential can be key to uncovering undiscovered gems in the US market.

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

The United States market has shown robust performance, climbing 2.5% in the last week and achieving a 26% increase over the past year, with earnings projected to grow by 17% annually in the coming years. In such a dynamic environment, dividend stocks can offer investors attractive yields while providing potential stability and income generation for their portfolios.

Shareholders appeared unconcerned with Dynatrace, Inc.'s ( NYSE:DT ) lackluster earnings report last week. We think...

Some Hamilton Insurance Group, Ltd. ( NYSE:HG ) shareholders may be a little concerned to see that the Independent...

Insiders who bought NetSol Technologies, Inc. ( NASDAQ:NTWK ) stock in the last 12 months were richly rewarded last...

Readers hoping to buy NIKE, Inc. ( NYSE:NKE ) for its dividend will need to make their move shortly, as the stock is...

The market for Haemonetics Corporation's ( NYSE:HAE ) shares didn't move much after it posted weak earnings recently...

Some Rambus Inc. ( NASDAQ:RMBS ) shareholders may be a little concerned to see that the EVP & COO, Xianzhi Fan...

Progyny (NasdaqGS:PGNY) announced a US$200 million share repurchase program approved by its Board. The authorization allows the company to buy back its common stock at its discretion over time. This capital allocation decision signals management’s view of the business and potential impact on shareholder value. Progyny focuses on fertility and family building benefits, a segment that sits at the intersection of healthcare, employer benefits, and demographic trends. As more employers look to...

Waste Management (NYSE:WM) has appointed Tara Hemmer as Executive Vice President and Chief Operating Officer. Hemmer will oversee the company’s operating platform along with its Sustainability businesses. Rafael Carrasco, who leads WM Healthcare Solutions, is retiring, prompting reporting and organizational changes. These leadership moves reflect an internal reorganization affecting both core operations and sustainability focused units. Waste Management, traded on the NYSE under the ticker...

Wondering if Extra Space Storage is fairly priced or if the stock still offers value at current levels? This breakdown focuses squarely on what you are getting for the price you pay. The stock last closed at US$143.99, with returns of 2.6% over 7 days, 1.3% over 30 days, 9.9% year to date and 1.9% over 1 year. This gives some context before comparing that price to underlying value. Recent coverage of Extra Space Storage has centered on its position within the Specialized REITs space and how...

The Morning Bull - US Market Morning Update Wednesday, May, 27 2026 US stock futures are pointing higher this morning, with contracts linked to the S&P 500 and Nasdaq 100 up around 0.5% to 0.8%, as investors weigh stronger global growth signals against rising interest rate pressures. In Taiwan, retail sales are up 5.2% over the past year and industrial production is 14.16% higher, hinting at steady demand for electronics and other goods that feed into US tech and chip stocks. At the same...

Northwest Bancshares (NasdaqGS:NWBI) has appointed Chad Ballard as Chief Information Officer. Ballard brings extensive experience from large financial institutions to the bank's technology leadership team. The CIO appointment reflects the growing importance of digital capabilities and information security in banking. For a regional banking company like Northwest Bancshares, technology is now central to how customers access services, including mobile apps and online account management...

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data. The approval covers advanced cancer care and expands the test's use as a companion diagnostic across multiple cancer types. The platform uses AI-enabled multiomic technology to combine genomic and epigenomic insights in a single liquid biopsy. Guardant Health focuses on liquid biopsy...

If you are wondering whether MercadoLibre stock still justifies its current price, the key question is how that price stacks up against the value implied by its fundamentals. The shares last closed at US$1,648.04, with the price rising about 3.3% over the past week but declining around 10.2% over the past month and about 16.5% year to date, while the return over the past year is a decline of roughly 35.5% and the 3 and 5 year returns are about 31.9% and 20.4% respectively. These moves have...

Wondering if Napco Security Technologies at US$37.09 still offers value after its recent run? This article walks through what the current price might be implying about the stock. The stock is up 3.5% over the past week, but down 19.2% over the past month and down 10.4% year to date. It still shows a 32.9% gain over the last year and 1.9% over three years, with a 133.2% return over five years. Recent news coverage has focused on Napco Security Technologies as investors reassess growth...

If you are wondering whether NiSource at around US$47.80 is priced for more growth or already reflects high expectations, the starting point is understanding what the current market price is implying about its value. The stock has delivered a 0.8% gain over the last 7 days, is down 0.4% over the past month, and has returns of 13.4% year to date, 24.9% over 1 year, 97.7% over 3 years and 121.6% over 5 years, which may influence how much future upside or downside investors see from...

Thermon Group Holdings, Inc. recently reported its fourth-quarter and full-year results to March 31, 2026, with sales rising to US$148.33 million for the quarter and US$536.26 million for the year, while net income fell to US$2.75 million and US$44.57 million respectively compared with the prior year. The combination of higher revenue but lower net income and earnings per share highlights pressure on profitability even as Thermon continues to grow its top line. We’ll now examine how...

Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.